Fig. 2From: Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialSwimmer plot of dynamic response assessment. Each bar is an individual patient. AML acute myeloid leukemia, HSCT hematopoietic stem cell transplantation, MRD measurable residual disease, CR complete remission, NR non-remission, PR partial remissionBack to article page